Cholesterol Reduction in Seniors Program (CRISP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000477
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : February 18, 2016
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

Brief Summary:
To conduct a pilot study to determine whether lowering elevated serum cholesterol levels with 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors reduced mortality due to the sequelae of atherosclerotic cardiovascular disease in older men and women.

Condition or disease Intervention/treatment Phase
Atherosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Hypercholesterolemia Myocardial Ischemia Drug: lovastatin Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Primary Purpose: Prevention
Study Start Date : July 1990
Actual Study Completion Date : June 1992

Resource links provided by the National Library of Medicine

Drug Information available for: Lovastatin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years to 100 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Men and women, ages 65 and older, with elevated low-density lipoprotein cholesterol levels between 159 and 221 mg/dl at entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00000477

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
OverallOfficial: William Applegate University of Tennessee
OverallOfficial: John Crouse Bowman Gray School of Medicine
OverallOfficial: Donald Hunninghake University of Minnesota - Clinical and Translational Science Institute
OverallOfficial: Robert Knopp University of Washington
OverallOfficial: John LaRosa George Washington University

Publications: Identifier: NCT00000477     History of Changes
Other Study ID Numbers: 66
U01HL044315 ( U.S. NIH Grant/Contract )
First Posted: October 28, 1999    Key Record Dates
Last Update Posted: February 18, 2016
Last Verified: June 1992

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors